

YOUR INVITATION TO ATTEND:

GeneSight® in Clinical Practice

A MYRIAD GENETICS SPEAKER PRESENTATION

A clinical and scientific discussion focusing on the basics of pharmacogenomics and review of the GeneSight® Psychotropic report and clinical data. Q&A to follow.



PRESENTER

Ashlea Brewer, APRN, PMHNP

DATE & TIME

Thursday, June 8, 2023
7:00pm

RSVP

Please RSVP by
June 5, 2023

LOCATION

Mazen's Grill
5818 Johnston St.
Lafayette, LA 70503

TO REGISTER

George Johnson
Molecular Sales Consultant
george.johnson@myriad.com
(225) 936-5335

This event is not open to the general public. If you were not the original recipient of this invitation, please contact a GeneSight representative with your request to attend.

The GeneSight® Psychotropic test is a genetics-based decision support tool that analyzes clinically important genetic variations that may affect your patient's outcomes with certain psychiatric medications. Use of the GeneSight Psychotropic test can help inform your medication selection. The results show which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on your patient's genetic makeup. The clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test have been evaluated in seven published, peer-reviewed clinical trials. In the GUIDED study, patients in the GeneSight arm experienced an 11% relative improvement in symptoms, a 30% relative improvement in response rates, and a 50% relative improvement in remission rates compared to treatment as usual at week 8.



6960 Cintas Blvd
Mason, OH 45040
866.260.2394



www.genesight.com